The India eye drop market size reached USD 211.15 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 304.46 Million by 2033, exhibiting a growth rate (CAGR) of 4.15% during 2025-2033. The rising prevalence of eye disorders, increasing screen time, and a growing aging population are driving the India eye drop market share. Additionally, expanding healthcare infrastructure and government initiatives are improving access to ophthalmic treatments, further catalyzing demand for prescription and over the counter (OTC) eye drops.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024 |
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024 | USD 211.15 Million |
Market Forecast in 2033 | USD 304.46 Million |
Market Growth Rate 2025-2033 | 4.15% |
Growing Aging Population
Elderly individuals are more prone to age-related eye conditions such as cataracts, glaucoma, and macular degeneration. These conditions require continuous management using medicated eye drops for treatment and symptom relief. With age, natural tear production decreases, leading to a higher prevalence of dry eye syndrome. Lubricating and artificial tear eye drops are widely used to alleviate discomfort and maintain eye health. Many seniors experience increased intraocular pressure, necessitating prescription eye drops for glaucoma management and vision preservation. Post-surgical eye care for cataract patients also contributes to the rising demand for specialized eye drops. The rising life expectancy is increasing the elderly population, further accelerating the India eye drop market growth. In March 2024, Roche launched Vabysmo in India to treat neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). This bispecific antibody targets Ang-2 and VEGF-A, reducing injection frequency and improving vision outcomes, enhancing retinal disease treatment accessibility. Growing awareness about geriatric eye health is prompting more regular checkups and ophthalmologist-recommended eye drop usage. Government healthcare initiatives focusing on senior citizens are supporting access to affordable ophthalmic treatments. Pharmaceutical advancements are introducing preservative-free and herbal eye drops, catering to the needs of elderly patients.
Rising Prevalence of Eye Disorders
The growing incidences of eye illnesses is significantly influencing the India eye drop market outlook. Increasing cases of dry eye syndrome, conjunctivitis, glaucoma, and cataracts are leading to higher demand for eye drops. Many individuals suffer from eye infections and allergies due to pollution and environmental factors. India accounts for approximately 25% of the world's visually impaired population, highlighting the urgent need for effective eye care solutions. Eye drops are essential for managing redness, irritation, and bacterial or viral infections effectively. The growing diabetic population is also contributing to higher cases of diabetic retinopathy and related conditions. Nearly 13% of diabetic individuals experience diabetic retinopathy, increasing the demand for specialized eye drops to manage intraocular pressure, inflammation, and post-surgical eye care. Prolonged screen exposure is further increasing the occurrence of digital eye strain and fatigue. Lubricating and artificial tear drops are widely used to alleviate dryness and discomfort caused by screens. Rising awareness about early diagnosis and treatment is encouraging people to opt for medicated eye drops.
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the regional level for 2025-2033. Our report has categorized the market based on type, drug class, disease indication, and distribution channel.
Type Insights:
The report has provided a detailed breakup and analysis of the market based on the type. This includes prescription, and over the counter.
Drug Class Insights:
A detailed breakup and analysis of the market based on the drug class have also been provided in the report. This includes antiallergy, anti-inflammatory, antiglaucoma, anti-VEGF, and others.
Disease Indication Insights:
The report has provided a detailed breakup and analysis of the market based on the disease indication. This includes dry eye diseases, glaucoma, eye allergy, eye infections, retinal disorders, and others.
Distribution Channel Insights:
A detailed breakup and analysis of the market based on the distribution channel have also been provided in the report. This includes hospitals pharmacy, retail pharmacy, and online pharmacy.
Regional Insights:
The report has also provided a comprehensive analysis of all the major regional markets, which include North India, South India, East India, and West India.
The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Million USD |
Scope of the Report |
Exploration of Historical Trends and Market Outlook, Industry Catalysts and Challenges, Segment-Wise Historical and Future Market Assessment:
|
Types Covered | Prescription, Over the Counter |
Drug Classes Covered | Antiallergy, Anti-Inflammatory, Antiglaucoma, Anti-VEGF, Others |
Disease Indications Covered | Dry Eye Diseases, Glaucoma, Eye Allergy, Eye Infections, Retinal Disorders, Others |
Distribution Channels Covered | Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy |
Regions Covered | North India, South India, East India, West India |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report:
Key Benefits for Stakeholders: